S&P 500   3,769.96 (-2.07%)
DOW   30,433.44 (-1.63%)
QQQ   321.13 (-2.27%)
AAPL   142.55 (-0.43%)
MSFT   232.36 (+0.01%)
FB   273.28 (-3.11%)
GOOGL   1,821.35 (-4.54%)
AMZN   3,251.36 (-2.25%)
TSLA   875.40 (-0.87%)
NVDA   517.02 (-3.79%)
BABA   262.00 (-1.47%)
CGC   38.19 (+7.52%)
GE   10.76 (-4.69%)
MU   75.68 (-4.82%)
AMD   89.29 (-5.72%)
NIO   57.32 (-4.96%)
T   29.08 (-2.25%)
F   10.79 (-3.57%)
ACB   11.41 (+6.94%)
BA   192.94 (-4.51%)
DIS   163.06 (-3.83%)
NFLX   533.00 (-5.15%)
GILD   65.59 (-1.66%)
S&P 500   3,769.96 (-2.07%)
DOW   30,433.44 (-1.63%)
QQQ   321.13 (-2.27%)
AAPL   142.55 (-0.43%)
MSFT   232.36 (+0.01%)
FB   273.28 (-3.11%)
GOOGL   1,821.35 (-4.54%)
AMZN   3,251.36 (-2.25%)
TSLA   875.40 (-0.87%)
NVDA   517.02 (-3.79%)
BABA   262.00 (-1.47%)
CGC   38.19 (+7.52%)
GE   10.76 (-4.69%)
MU   75.68 (-4.82%)
AMD   89.29 (-5.72%)
NIO   57.32 (-4.96%)
T   29.08 (-2.25%)
F   10.79 (-3.57%)
ACB   11.41 (+6.94%)
BA   192.94 (-4.51%)
DIS   163.06 (-3.83%)
NFLX   533.00 (-5.15%)
GILD   65.59 (-1.66%)
S&P 500   3,769.96 (-2.07%)
DOW   30,433.44 (-1.63%)
QQQ   321.13 (-2.27%)
AAPL   142.55 (-0.43%)
MSFT   232.36 (+0.01%)
FB   273.28 (-3.11%)
GOOGL   1,821.35 (-4.54%)
AMZN   3,251.36 (-2.25%)
TSLA   875.40 (-0.87%)
NVDA   517.02 (-3.79%)
BABA   262.00 (-1.47%)
CGC   38.19 (+7.52%)
GE   10.76 (-4.69%)
MU   75.68 (-4.82%)
AMD   89.29 (-5.72%)
NIO   57.32 (-4.96%)
T   29.08 (-2.25%)
F   10.79 (-3.57%)
ACB   11.41 (+6.94%)
BA   192.94 (-4.51%)
DIS   163.06 (-3.83%)
NFLX   533.00 (-5.15%)
GILD   65.59 (-1.66%)
S&P 500   3,769.96 (-2.07%)
DOW   30,433.44 (-1.63%)
QQQ   321.13 (-2.27%)
AAPL   142.55 (-0.43%)
MSFT   232.36 (+0.01%)
FB   273.28 (-3.11%)
GOOGL   1,821.35 (-4.54%)
AMZN   3,251.36 (-2.25%)
TSLA   875.40 (-0.87%)
NVDA   517.02 (-3.79%)
BABA   262.00 (-1.47%)
CGC   38.19 (+7.52%)
GE   10.76 (-4.69%)
MU   75.68 (-4.82%)
AMD   89.29 (-5.72%)
NIO   57.32 (-4.96%)
T   29.08 (-2.25%)
F   10.79 (-3.57%)
ACB   11.41 (+6.94%)
BA   192.94 (-4.51%)
DIS   163.06 (-3.83%)
NFLX   533.00 (-5.15%)
GILD   65.59 (-1.66%)
Log in
NASDAQ:CDNA

CareDx Stock Forecast, Price & News

$76.94
-2.02 (-2.56 %)
(As of 01/27/2021 02:34 PM ET)
Add
Compare
Today's Range
$70.99
Now: $76.94
$78.84
50-Day Range
$64.91
MA: $77.14
$95.60
52-Week Range
$13.04
Now: $76.94
$99.83
Volume81,862 shs
Average Volume837,044 shs
Market Capitalization$3.79 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.84
CareDx, Inc. discovers, develops, and commercializes healthcare solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; and AlloMap Heart, a gene expression solution for heart transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and solid organs. In addition, it offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a solution for use in transplantation diagnostic testing. Further, the company provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI and Waitlist Management solutions. It offers its products directly to customers, as well as through third-party distributors. The company has a license agreement with Illumina, Inc. for the development, commercialization, and distribution of sequencing product line for use in transplantation diagnostic testing; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss, as well as a partnership with IDbyDNA, Inc. for the development of metagenomic infectious disease testing. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
CareDx logo

MarketRank

Overall MarketRank

1.18 out of 5 stars

Medical Sector

846th out of 1,926 stocks

Medical Laboratories Industry

18th out of 39 stocks

Analyst Opinion: 2.6Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDNA
CUSIPN/A
Phone415-287-2300
Employees306
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$127.07 million
Book Value$2.33 per share

Profitability

Net Income$-21,970,000.00

Miscellaneous

Market Cap$3.79 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$76.94
-2.02 (-2.56 %)
(As of 01/27/2021 02:34 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CDNA News and Ratings via Email

Sign-up to receive the latest news and ratings for CDNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CareDx (NASDAQ:CDNA) Frequently Asked Questions

How has CareDx's stock been impacted by COVID-19?

CareDx's stock was trading at $18.94 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CDNA stock has increased by 307.6% and is now trading at $77.19.
View which stocks have been most impacted by COVID-19
.

Is CareDx a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CareDx stock.
View analyst ratings for CareDx
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than CareDx?

Wall Street analysts have given CareDx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CareDx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is CareDx's next earnings date?

CareDx is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for CareDx
.

How were CareDx's earnings last quarter?

CareDx, Inc (NASDAQ:CDNA) issued its earnings results on Thursday, October, 29th. The company reported ($0.06) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.06). The firm earned $53.40 million during the quarter, compared to analyst estimates of $51.90 million. CareDx had a negative trailing twelve-month return on equity of 10.95% and a negative net margin of 11.79%. The company's revenue was up 58.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.02 EPS.
View CareDx's earnings history
.

What guidance has CareDx issued on next quarter's earnings?

CareDx updated its fourth quarter 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $58.4-58.6 million, compared to the consensus revenue estimate of $53.21 million.

What price target have analysts set for CDNA?

6 brokerages have issued 1-year price objectives for CareDx's stock. Their forecasts range from $35.00 to $94.00. On average, they anticipate CareDx's stock price to reach $72.00 in the next year. This suggests that the stock has a possible downside of 6.7%.
View analysts' price targets for CareDx
or view Wall Street analyst' top-rated stocks.

Who are some of CareDx's key competitors?

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Square (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).

Who are CareDx's key executives?

CareDx's management team includes the following people:
  • Dr. Peter Maag, Exec. Chairman (Age 54, Pay $1.08M)
  • Dr. Reginald Seeto, Pres, CEO & Director (Age 49, Pay $826k)
  • Ms. Sasha King M.B.A., Chief Marketing Officer (Age 35, Pay $509.2k)
  • Mr. Marcel Konrad, Interim Chief Financial Officer (Age 46)

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

Who are CareDx's major shareholders?

CareDx's stock is owned by many different retail and institutional investors. Top institutional shareholders include Zweig DiMenna Associates LLC (0.29%), TIAA FSB (0.16%), Conestoga Capital Advisors LLC (0.06%), Exchange Traded Concepts LLC (0.05%), Juncture Wealth Strategies LLC (0.03%) and Strs Ohio (0.02%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Michael Goldberg, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King and William A Hagstrom.
View institutional ownership trends for CareDx
.

Which institutional investors are selling CareDx stock?

CDNA stock was sold by a variety of institutional investors in the last quarter, including Zweig DiMenna Associates LLC, Conestoga Capital Advisors LLC, Juncture Wealth Strategies LLC, Mesirow Financial Investment Management Inc., Pacer Advisors Inc., and Contravisory Investment Management Inc.. Company insiders that have sold CareDx company stock in the last year include Michael Brian Bell, Michael Goldberg, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, and William A Hagstrom.
View insider buying and selling activity for CareDx
or view top insider-selling stocks.

Which institutional investors are buying CareDx stock?

CDNA stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio, Exchange Traded Concepts LLC, Nisa Investment Advisors LLC, and TIAA FSB.
View insider buying and selling activity for CareDx
or or view top insider-buying stocks.

How do I buy shares of CareDx?

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CareDx's stock price today?

One share of CDNA stock can currently be purchased for approximately $77.19.

How big of a company is CareDx?

CareDx has a market capitalization of $3.80 billion and generates $127.07 million in revenue each year. The company earns $-21,970,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. CareDx employs 306 workers across the globe.

What is CareDx's official website?

The official website for CareDx is www.caredxinc.com.

How can I contact CareDx?

CareDx's mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-287-2300 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.